Debt-to-Equity Ratio

Novo Nordisk’s debt-to-equity ratio of 0.72x means the company uses 0.72 dollars of debt for every dollar of shareholders’ equity, indicating a moderate reliance on borrowing relative to its own capital.

Compared to the healthcare sector median of 0.43x, Novo Nordisk sits at the 64th percentile among peers, meaning its leverage is higher than roughly two-thirds of similar companies. No year-over-year or quarter-over-quarter changes are available, and the trend direction over the last eight quarters is also not provided, so no short-term movement can be assessed. The combination of a debt-to-equity ratio above the sector median with no observable trend suggests a higher-than-average leverage level, which can amplify risk if earnings decline but offers no insight into whether that risk is increasing or decreasing. This metric does not contradict the overall NEUTRAL verdict, as the moderately elevated leverage is a factor that tempers both upside potential and downside exposure, aligning with a balanced assessment.

Frequently Asked Questions

Closest Sector Peers